Corinne Nevinny - Insulet Independent Director
| PODD Stock | USD 168.74 2.48 1.49% |
Director
Ms. Corinne Nevinny is Independent Director of the Company. Corinne Nevinny was the General Partner of LMNVC since August 2010. LMNVC is a seed venture fund making earlyround investments in women owned or run startup companies that have products or services that improve quality of life, including clean, green, health, wellness, fitness and education oriented businesses. From 2003 to 2010, she held multiple positions at Edwards Lifesciences Corporationrationration, including General Manager Cardiac Surgery Systems, President of Global Operations, and Chief Financial Officer and Treasurer. Prior to joining Edwards, Ms. Nevinny held various finance and investment banking positions. Ms. Nevinny is a member of the Board of Trustees and Executive Committee of the United States Olympic and Paralympic Foundation and serves on the Board of Directors of Restorsea LLC. She previously served on the Board of privatelyheld nVision, as well as public company Boards, including Edwards Life Sciences Corporation, Avanir Pharmaceuticals, Inc., Neurocrine Biosciences, Onyx Pharmaceuticals, Inc., and SangStat Medical Corporationration and chaired the Audit Committees for Avanir, Neurocrine and Onyx since 2019.
| Age | 57 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 100 Nagog Park, Acton, MA, United States, 01720 |
| Phone | 978 600 7000 |
| Web | https://www.insulet.com |
Insulet Management Efficiency
The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Daniel Starks | Abbott Laboratories | 66 | |
| Roch Doliveux | Stryker | 64 | |
| Kevin Sullivan | Penumbra | 73 | |
| Mark Foletta | DexCom Inc | 57 | |
| Kevin Dallas | Align Technology | 54 | |
| Bridget ORourke | Penumbra | 52 | |
| Frederic Moll | Shockwave Medical | N/A | |
| Walter Wang | Penumbra | 47 | |
| Thomas Harkin | Masimo | 77 | |
| John Stratton | Abbott Laboratories | 60 | |
| Aimee Weisner | Glaukos Corp | 51 | |
| William Osborn | Abbott Laboratories | 73 | |
| Sherilyn McCoy | Stryker | 62 | |
| Sally Blount | Abbott Laboratories | 59 | |
| Jonathan Silverstein | Glaukos Corp | 49 | |
| Howard Cox | Stryker | 74 | |
| Rebecca Robertson | Tandem Diabetes Care | 57 | |
| Surbhi Sarna | Penumbra | 34 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
| Gregory Santora | Align Technology | 66 | |
Management Performance
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.0609 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
| Sally Crawford, Lead Independent Director | ||
| Philip Hildale, Senior Care | ||
| John Fallon, Independent Director | ||
| Mark Field, Senior CTO | ||
| Laetitia Cousin, Quality Affairs | ||
| Deborah Gordon, Vice President Investor Relations and Corporate Communications | ||
| Daniel Levangie, Independent Director | ||
| James Mullen, Independent Director | ||
| John Kapples, Senior Vice President General Counsel, Secretary | ||
| Patrick Sullivan, CEO and President and Director | ||
| Wayde McMillan, CFO, Executive Vice President | ||
| Charles Liamos, Director of Advanced Technology and Director | ||
| Michael Levitz, CFO | ||
| Bradley Thomas, Executive VP of HR and Organizational Devel. | ||
| Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
| David Lemoine, Independent Director | ||
| James Hollingshead, CEO President | ||
| Jessica Hopfield, Director | ||
| David Colleran, Vice President General Counsel | ||
| Brittany Bradrick, Vice President - Strategy and Corporate Development | ||
| Bret Christensen, Chief Commercial Officer | ||
| Deborah CPA, Vice Relations | ||
| Timothy Scannell, Director | ||
| Michael Minogue, Independent Director | ||
| Steven Sobieski, Independent Director | ||
| Aiman AbdelMalek, Senior Vice President Advanced Technology and Engineering | ||
| Corinne Nevinny, Independent Director | ||
| Regina Sommer, Independent Director | ||
| Mark Licari, Vice President - Global Manufacturing and Operations | ||
| Prem Singh, Senior Operations | ||
| Angela Wiczek, Senior Communications | ||
| Lauren Budden, Chief VP | ||
| Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
| Joseph Zakrzewski, Independent Director | ||
| Shacey Petrovic, Chief Commercial Officer | ||
| Trang Ly, Vice President and Medical Director |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | ||||
| Return On Asset | 0.0609 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 12.91 B | ||||
| Shares Outstanding | 70.02 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 99.69 % | ||||
| Number Of Shares Shorted | 3.12 M | ||||
| Price To Book | 16.75 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insulet using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.043 | Earnings Share 2.93 | Revenue Per Share 24.331 | Quarterly Revenue Growth 0.379 | Return On Assets 0.0609 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.